Nicox launches RetnaGene test portfolio nationwide
Nicox Inc. announced the national brand launch of RetnaGene tests in the U.S., according to an announcement from Nicox S.A. and Sequenom Inc.
As detailed in a press release, the RetnaGene test portfolio includes RetnaGene AMD and RetnaGene LR, which evaluate age-related macular degeneration risk.
“Expanding access to the RetnaGene portfolio of tests is an important milestone in the progress of the Nicox Ophthalmic Diagnostics franchise in the U.S.,” Jerry St. Peter, executive vice president and general manager of Nicox Inc., said in the release. “AMD is a leading cause of blindness in the U.S. and is estimated to affect over 15 million Americans, including 10% to 15% suffering from an advanced form of the disease.
“The RetnaGene tests allow for improved patient management, by examining the most relevant genetic markers for a more accurate prediction of advanced AMD risk,” St. Peter continued. “Both the RetnaGene tests and our groundbreaking test for the early detection of Sjögren’s syndrome, Sjö, will be supported by our rapidly expanding specialist sales force.”
“We are pleased with the timely progress of our partnership with Nicox and we are confident in Nicox’s ability to successfully expand access to the RetnaGene portfolio of tests in the ophthalmic arena in the U.S.,” William Welch, CEO of Sequenom Inc., said in the release.
Sequenom Laboratories granted Nicox Inc. promotion and marketing rights for the tests in January.